GLPwatch
Papers (12034)
Page 136 of 201, ranked by citation count.
- Management of Obesity in Psoriasis Consultations.
- GLP1 receptor agonism alters growth and therapeutic response in prostate cancer.
- Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
- Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
- Acute GLP-1 Agonism Induces Arrhythmogenic Electrical Activity in Aged Mice Heart Through Impaired Cellular Na+ and Ca2+ Handlings: The Role of CK2 Hyperphosphorylation.
- Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study.
- Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.
- Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
- [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.
- [Acute pancreatitis in a patient treated with liraglutide].
- Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
- Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
- Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity.
- Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
- [Anti-obesity drugs : from previous disappointments to new hopes].
- Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
- Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.
- Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.
- GLP-1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy.
- The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
- Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.
- Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
- Expression of NUCB2/nesfatin-1 in the taste buds of rats.
- Ozempic <i>v</i> Mounjaro: what is the difference between semaglutide and tirzepatide?
- Glucagon-like peptide-1 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: A TriNetX retrospective analysis.
- A Review of First-Generation Obesity Medications.
- Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.
- The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
- Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence.
- Drug-Induced Liver Injury Due to Dulaglutide Use.
- Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
- Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model.
- The diabetic muscle.
- Letter to the Editor: Comment on "The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial" by Kramer C.K., et al.
- Older Adults' Views on Insurance Coverage for Weight Management Medications.
- Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study.
- Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
- Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
- Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
- Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition.
- Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.
- Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
- The STEP 1 trial for weight loss: a step change in treating obesity?
- Liraglutide and Liver Injury: Rare Case Report with Literature Review.
- Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.
- 12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.
- Liraglutide inhibits the proliferation of rat hepatic stellate cells under high glucose conditions by suppressing the ERK signaling pathway.
- The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis.
- Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.
- A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.
- Effect of exenatide on gastric emptying and graft survival in islet allograft recipients.
- The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
- The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes.
- The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.
- Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.
- Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.
- The administration of Exendin-4 and CCK affects food intake differentially in female and male rats tested on an alternate day fasting paradigm.